Pacific Biosciences of California, Inc. Announces First

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pacific Biosciences of California, Inc. Announces First Quarter 2016 Financial Results

MENLO PARK, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB ) today announced financial results for its first quarter ended March 31, 2016.

Revenue for the first quarter of 2016 increased by 8% to $19.1 million compared to $17.6 million for the first quarter of 2015. Product and service revenue for the first quarter of 2016 was $15.5 million, compared to $14.0 million for the first quarter of 2015. Revenue for the first quarter of each of 2016 and 2015 reflected $3.6 million of contractual revenue amortization from the upfront Roche payment pursuant to the Roche agreement.

Gross profit increased by $3.6 million to $9.5 million for the first quarter of 2016, resulting in a gross margin of 49.7%, compared to gross profit of $5.9 million and a gross margin of 33.6% for the first quarter of 2015. The growth in gross profit and margin was primarily driven by the higher margin sales of the company’s Sequel TM System which was launched in the fourth quarter of 2015.

Operating expenses for the first quarter of 2016 totaled $28.1 million, compared to $25.3 million for the first quarter of 2015. Operating expenses for the first quarter of 2016 and 2015 included non-cash stock-based compensation of $4.1 million and $3.0 million, respectively.

Net loss for the first quarter of 2016 was $19.4 million, compared to $20.2 million for the first quarter of 2015.

Cash and investments at March 31, 2016 totaled $91.5 million, compared to $82.3 million at December 31, 2015. 

Quarterly Conference Call Information 

Management will host a quarterly conference call to discuss its first quarter 2016 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/ .

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB ) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT ® ) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio ® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.  More information is available at www.pacb.com

Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products for Roche, the attributes and sequencing advantages of SMRT Technology and PacBio sequencing systems and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)
           
  Quarter Ended March 31,
  2016   2015
Revenue:          
Product revenue $   12,379     $   11,308  
Service and other revenue     3,152         2,741  
Contractual revenue     3,596         3,596  
Total revenue     19,127         17,645  
Cost of Revenue:          
Cost of product revenue     6,880         9,732  
Cost of service and other revenue     2,743         1,986  
Total cost of revenue     9,623         11,718  
Gross profit     9,504         5,927  
Operating Expense:          
Research and development     16,361         14,483  
Sales, general and administrative     11,708         10,772  
Total operating expense     28,069         25,255  
Operating loss     (18,565 )       (19,328 )
Interest expense     (779 )       (697 )
Other expense, net     (8 )       (148 )
Net loss $   (19,352 )   $   (20,173 )
Basic and diluted net loss per share $   (0.23 )   $   (0.27 )
Shares used in computing basic and diluted net loss per share     83,604         74,149  
Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)
             
  March 31,   December 31,
  2016   2015
Assets      
Cash and investments $ 91,531   $   82,270
Accounts receivable   8,009       5,245
Inventory   12,162       10,955
Prepaid and other current assets   7,351       12,071
Property and equipment   9,093       8,548
Long-term restricted cash   4,500       4,500
Other long-term Assets   7,529       7,518
Total Assets $ 140,175   $   131,107
             
Liabilities and Stockholders' Equity            
Accounts payable $ 4,734   $   4,749
Accrued expenses   13,644       15,551
Deferred service revenue   7,253       7,958
Deferred contractual revenue   8,539       12,134
Other liabilities   1,462       1,627
Financing derivative   551       600
Notes payable   15,216       14,948
Stockholders' equity   88,776       73,540
Total Liabilities and Stockholders' Equity $ 140,175   $   131,107
             

Contact: Trevin Rard 650.521.8450 ir@pacificbiosciences.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 159

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 44

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 8

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 100

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 103

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 75

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 119

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 74

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 0

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
APEC in Shenzhen Puts Trade Openness Back in Focus

Updated Category News Views 68

Shenzhen is hosting a familiar but consequential argument: prosperity gets harder to share when trade channels clog up. At the 33rd Asia-Pacific Economic Cooperation Economic Leaders' Meeting on November 18, President Xi Jinping used the opening of the APEC CEO Summit to argue for peace, openness, innovation, mutual benefit and support for the WTO-centered multilateral...

Continue Reading

Top 5 Most Recently Viewed Articles

Join Us for Engaging Insights at the Boston IT Summit

Updated Category News Views 115

On November 7th, the Boston Cloud Connect Summit brought together industry heavyweights to tackle pressing issues in cybersecurity and artificial intelligence. With tech's rapid evolution, you know this ain't just some run-of-the-mill conference; it’s a showcase of brains tackling real threats. Cybersecurity Insights: Joe Flores at the Helm Joe Flores, Massachusetts...

Continue Reading
Revolutionizing Fitness and Entertainment: HYROX Partners with Legendz

Updated Category News Views 306

HYROX Teams Up with Legendz for Unmatched Experiences HYROX, a leader in the world of fitness racing, has announced an exciting partnership with Legendz Social Sportsbook & Casino, aiming to merge the world of competitive fitness with top-tier entertainment. This collaboration will not only uplift the profile of fitness events but also enhance fan engagement like never...

Continue Reading
DXC Technology Teams with Ferrari for Advanced Automotive HMI

Updated Category News Views 210

DXC Technology Partners with Ferrari for Next-Gen HMI Development DXC Technology (NYSE: DXC) has entered a groundbreaking partnership with Ferrari aimed at transforming the driver experience through advanced Human Machine Interface (HMI) systems in the latest automotive models. This collaboration allows DXC to leverage its extensive expertise in the automotive sector to...

Continue Reading
CEO Aman Narang's Selling Decision Raises Investor Interest

Updated Category News Views 250

Understanding the Recent Insider Sale at Toast A recent SEC filing has brought to light an important transaction involving Aman Narang, the CEO of Toast (NYSE: TOST). On a notable day, Narang sold 1,732 shares of Toast, amounting to a total value exceeding $61,000. This insider action inevitably attracts the attention of seasoned investors and market observers alike....

Continue Reading
Blue Cross and Blue Shield of Montana: Quality Health Coverage For All

Updated Category News Views 259

Blue Cross and Blue Shield of Montana Enhances Health Offerings Blue Cross and Blue Shield of Montana (BCBSMT) is dedicated to providing quality individual and family health insurance plans across Montana as the open enrollment period commences. Experience and Availability of Plans For over 85 years, BCBSMT has been a cherished provider in Montana, actively extending its...

Continue Reading
om Blog Section End -->